- Home
- SNTI vs FEDU Comparison
SNTI vs FEDU Comparison
Compare SNTI & FEDU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SNTI
- FEDU
- Stock Information
- Founded
- SNTI 2016
- FEDU 2007
- Country
- SNTI United States
- FEDU China
- Employees
- SNTI N/A
- FEDU N/A
- Industry
- SNTI Biotechnology: Pharmaceutical Preparations
- FEDU
- Sector
- SNTI Health Care
- FEDU
- Exchange
- SNTI Nasdaq
- FEDU NYSE
- Market Cap
- SNTI 21.3M
- FEDU 22.2M
- IPO Year
- SNTI N/A
- FEDU 2017
- Fundamental
- Price
- SNTI $3.96
- FEDU $10.17
- Analyst Decision
- SNTI Strong Buy
- FEDU
- Analyst Count
- SNTI 1
- FEDU 0
- Target Price
- SNTI $12.00
- FEDU N/A
- AVG Volume (30 Days)
- SNTI 30.3K
- FEDU 3.3K
- Earning Date
- SNTI 03-20-2025
- FEDU 12-20-2024
- Dividend Yield
- SNTI N/A
- FEDU 22.42%
- EPS Growth
- SNTI N/A
- FEDU N/A
- EPS
- SNTI N/A
- FEDU 0.12
- Revenue
- SNTI N/A
- FEDU $27,971,139.00
- Revenue This Year
- SNTI $11.52
- FEDU N/A
- Revenue Next Year
- SNTI $78.57
- FEDU N/A
- P/E Ratio
- SNTI N/A
- FEDU $85.33
- Revenue Growth
- SNTI N/A
- FEDU 141.14
- 52 Week Low
- SNTI $1.52
- FEDU $7.41
- 52 Week High
- SNTI $16.94
- FEDU $22.70
- Technical
- Relative Strength Index (RSI)
- SNTI 45.36
- FEDU 48.25
- Support Level
- SNTI $3.92
- FEDU $9.78
- Resistance Level
- SNTI $4.50
- FEDU $10.77
- Average True Range (ATR)
- SNTI 0.26
- FEDU 0.53
- MACD
- SNTI -0.03
- FEDU 0.04
- Stochastic Oscillator
- SNTI 20.59
- FEDU 49.43
About SNTI Senti Biosciences Inc.
Senti Biosciences Inc is a clinical-stage biotechnology company developing next-generation cell and gene therapies engineered with their gene circuit platform technologies to fight challenging diseases. The product candidates utilize allogeneic chimeric antigen receptor natural killer (CAR-NK) cells outfitted with its gene circuit technologies in various oncology indications. The company product candidates include SENTI-202, a Logic Gated off-the-shelf CAR-NK cell therapy designed to target and eliminate cancer cells while sparing the healthy bone marrow; and SENTI-301A for the treatment of hepatocellular carcinoma.
About FEDU FOUR SEASONS EDUCATION (CAYMAN) INC SPON ADS EACH REP 10 ORD SHS(R/S)
Four Seasons Education (Cayman) Inc is engaged in the provision of after-school education services for kindergarten, elementary and middle school students. The Company derives its revenue from learning services, tourism services, and learning technology and content solutions. The company is a comprehensive educational enterprise that provides research practice services, educational informatization equipment, high-quality educational resources, and teacher training, as well as a digital publishing business, and continues to expand in educational research and educational informatization.